
United Kingdom · Medical devices startup
Quanta Dialysis Technologies is a medical technology company based in Warwick, United Kingdom, specializing in the design and development of portable hemodialysis systems.
Funding reportedLast round: Series D
Quanta Dialysis Technologies is a medical technology company based in Warwick, United Kingdom, specializing in the design and development of portable hemodialysis systems.
Founded in 2008, Quanta aims to make dialysis care more accessible and affordable for patients with kidney failure. The company operates globally, with a significant presence in the United States, and has raised approximately $425 million in funding from notable investors. The flagship product, the Quanta Dialysis System, is a compact and user-friendly hemodialysis machine suitable for various healthcare settings, including hospitals, clinics, and home use. It has received FDA 510(k) clearance and is recognized for its innovative Trinal Kidney TherapyTM. Quanta also provides services such as clinical training, regulatory assistance, and strategic partnerships to enhance its market reach and support healthcare providers. The company is committed to democratizing dialysis, ensuring high-quality kidney replacement therapy is available to all patients.
Funding, as reported
Quanta Dialysis Technologies filed 3 raises, $59M in all. Filings say how much was sold and to how many investors; they never name the investors.
From Quanta Dialysis Technologies's own website: 12 on the team.
What they build
Known for
hot swap replacementhealth carecare settingsclinical workflowremote monitoringmedical device regulationkidney carechronic caredistributionmanufacturingfda cleared dialysis systemhealthcare providersfda-clearedend stage renal diseasehemodialysis devicequanta dialysis system
Built with from their website
AtlassianMimecastMicrosoft AzureMicrosoft FabricMicrosoft Dynamics 365C#DocuSignJiraGoDaddy DomainsMiro
GoDaddy HostingJava
Add your raise, your deck and your story, and put Quanta Dialysis Technologies in front of investors. Or tell us what we have wrong.